Search

Your search keyword '"Fuwa, Nobukazu"' showing total 311 results
Start Over Author "Fuwa, Nobukazu" Language english
311 results on '"Fuwa, Nobukazu"'

16. Treatment results of alternating chemoradiotherapy followed by proton beam therapy boost combined with intra-arterial infusion chemotherapy for stage III–IVB tongue cancer

Author

Takayama, Kanako, Nakamura, Tatsuya, Takada, Akinori, Makita, Chiyoko, Suzuki, Motohisa, Azami, Yusuke, Kato, Takahiro, Hayashi, Yuichiro, Ono, Takashi, Toyomasu, Yutaka, Hareyama, Masato, Kikuchi, Yasuhiro, Daimon, Takashi, Mitsudo, Kenji, Tohnai, Iwai, and Fuwa, Nobukazu

Published
2016
Full Text
View/download PDF

21. Favorable Consolidative Effect of High-Dose Melphalan and Total-Body Irradiation Followed by Autologous Peripheral Blood Stem Cell Transplantation After Rituximab-Containing Induction Chemotherapy With In Vivo Purging in Relapsed or Refractory Follicular Lymphoma

Author

Kato, Harumi, Taji, Hirofumi, Ogura, Michinori, Kagami, Yoshitoyo, Oki, Yasuhiro, Tsujimura, Akane, Fuwa, Nobukazu, Kodaira, Takeshi, Seto, Masao, Yamamoto, Kazuhito, and Morishima, Yasuo

Published
2009
Full Text
View/download PDF

25. Endoscopic Laryngopharyngeal Surgery Combined with Endoscopic Submucosal Dissection as a Treatment Option for Superficial Hypopharyngeal Cancer with Suspected Synchronous Lymph Node Metastasis.

Author

Sugimoto, Shinya, Fuke, Tomohito, Kobayashi, Daisuke, Kaneko, Mamika, Temma, Taishi, Nomura, Tatsuma, Tsuda, Nobuyuki, Kawabata, Mayu, Matsushima, Ryutaro, Hisada, Hirohisa, Hayashi, Satoshi, Murabayashi, Toji, Oyamada, Jun, Kamei, Akira, Fuwa, Nobukazu, Yabana, Tadashi, Yamada, Hiroyuki, and Nakagawa, Hayato

Subjects
LYMPHATIC metastasis, LYMPHADENECTOMY, SPEECH disorders, HYPOPHARYNGEAL cancer, ENDOSCOPIC surgery, DEGLUTITION disorders
Abstract

We report 4 cases of hypopharyngeal cancer preoperatively suspected with synchronous lymph node metastases. Pathologic lymph node metastasis was confirmed in three of the four cases. All 4 cases underwent endoscopic laryngopharyngeal surgery (ELPS) combined with endoscopic submucosal dissection (ESD) and subsequent lymph node dissection as an optional treatment rather than the standard treatment. Peroral resection for primary site was selected because of the expected decline in quality of life (QoL) after radical surgery. Among 4 patients, one developed local recurrence; however, the other three remained recurrence-free and survived without any additional treatment. Furthermore, the patient who developed local recurrence had a recurrence-free survival for more than 5 years, with additional chemoradiation therapy. No disorders in speech, swallowing, or breathing was observed during the follow-up period. ELPS combined with ESD is generally indicated for laryngopharyngeal cancer without synchronous lymph node metastasis. However, this can be a treatment option for patients may wish to preserve a greater QoL after treatment. In the future, when more data on the results and long-term prognosis of this treatment are accumulated, it may be possible to discuss its validity further. [ABSTRACT FROM AUTHOR]

Published
2023
Full Text
View/download PDF

34. Initial Experience of Intra-Arterial Chemotherapy Using a Novel External Carotid Arterial Sheath System Combined with Radiotherapy and Systemic Chemotherapy for Locally Advanced Tongue Cancer.

Author

Nomura, Miwako, Fuwa, Nobukazu, Ito, Shintaro, Toyomasu, Yutaka, Takada, Akinori, Kobayashi, Daisuke, Fuke, Tomohito, Taniguchi, Masanori, Ii, Noriko, Uraki, Junji, and Yamada, Hiroyuki

Subjects
*CAROTID artery, *CLINICAL trials, *CANCER chemotherapy, *ANTINEOPLASTIC agents, *FLUOROURACIL, *TREATMENT effectiveness, *TUMOR classification, *MAXILLARY artery, *FLUOROSCOPY, *CISPLATIN, *DOCETAXEL, *COMBINED modality therapy, *RADIOTHERAPY, *PROGRESSION-free survival, *PATIENT safety, *INTRA-arterial infusions, *DRUG toxicity, TONGUE tumors
Abstract

Simple Summary: Surgery is the current standard for locally advanced tongue cancer. However, substantial impairment may occur even after treatment. Therefore, more effective and less toxic treatment strategies are needed to avoid a reduction in the patient's quality of life. This study aims to evaluate the efficacy and safety of a novel device that we have developed for retrograde intra-arterial chemotherapy (IACT) in patients with locally advanced tongue cancer. Our study demonstrates that the 3-year overall survival and progression-free survival were 81.6% and 74.2%, respectively. These results are not inferior to those of surgery, and no complications (e.g., cerebral infarction or catheter-related infection) have been associated with IACT were observed. We retrospectively evaluated the safety and effectiveness of an external carotid arterial sheath (ECAS) for intra-arterial chemotherapy (IACT) for locally advanced tongue cancer. Thirty-one patients with the Union for International Cancer Control's 8th TNM stage III–IV tongue cancer underwent IACT using the ECAS combined with RT and systemic chemotherapy with either cisplatin and fluorouracil (FP) or docetaxel, cisplatin, and fluorouracil (TPF) between October 2015 and February 2021. The ECAS was inserted retrogradely via the superficial temporal artery, and the tip was placed in the external carotid artery between the maxillary and facial arteries. A microcatheter was inserted into each tumor-feeding artery through the ECAS under fluoroscopy, wherein cisplatin 50 mg/m2 was administered. IACT was performed weekly with neutralization using sodium thiosulfate. Complete response of the primary lesion was achieved in 28/31 (90%) patients. The median follow-up for all patients was 39 months. The 3-year overall survival, progression-free survival, and local control rates were 81.6%, 74.2%, and 83.4%, respectively. Grade 3 and greater toxicities included oral mucositis (45%), neutropenia (39%), nausea (13%), anemia (10%), thrombocytopenia (10%), dry mouth (10%), and fever (3%). There were no severe complications associated with IACT. In conclusion, the ECAS is feasible and effective for locally advanced tongue cancer. [ABSTRACT FROM AUTHOR]

Published
2022
Full Text
View/download PDF

36. Proton beam therapy combined with retrograde intra-arterial infusion chemotherapy for an extremely rapid growing recurrent ameloblastic carcinoma: A case report

Author

Takayama, Kanako, Nakamura, Tatsuya, Takada, Akinori, Kato, Takahiro, Sakuma, Hideo, Mitsudo, Kenji, Fuwa, Nobukazu, and Murakami, Masao

Subjects
head and neck cancer, Articles, PBT, AC, radiotherapy, chemoradiotherapy, IAIC
Abstract

Ameloblastic carcinoma (AC) is a very rare malignant odontogenic tumor. Although surgical resection is generally performed, treatment approaches have not been established for recurrent cases. Chemotherapy and radiotherapy are positioned as adjunctive therapies, and few studies investigated definitive non-operative therapy. We present the case of a 71-year-old male with recurrent secondary-type AC arising from the right maxilla, who was treated with proton beam therapy (PBT; 71.4 Gy relative biological effectiveness in 32 fractions) combined with continuous intra-arterial infusion of cisplatin (40 mg/m2) and docetaxel (8 mg/m2). The patient experienced acute grade 3 mucositis, dermatitis and neutropenia, which were resolved within 3 months of treatment. Late adverse events were grade 1 skin atrophy, and grade 2 right optic nerve disorder and retinopathy. After ~8 years of treatment, the patient died from another cause but did not experience any relapse or metastasis during the follow-up period of 94 months. To the best of our knowledge, this is the first report of recurrent AC treated with PBT and intra-arterial infusion chemotherapy without any severe late adverse events. This combination therapy approach may be considered as an effective therapeutic option for inoperable AC.

Published
2020

Catalog

Books, media, physical & digital resources
See catalog results